Alembic Pharmaceutic Q4 net profit up 8.77% at Rs 251.37 cr
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2022/05/51d285564c9d945cf44f36e732b1f6ab.jpg)
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
The company reported standalone net profit of Rs 251.37 crore for the quarter ended March 31, 2022 as compared to Rs 231.11 crore in the same period last year, registering a year-on-year growth of 8.77 per cent. Net revenue of the company rose moderately by 12.71 per cent at Rs 1,304.32 crore in January-March quarter of this fiscal as against Rs 1,157.24 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 21.14 per cent to Rs 1,013.01 crore from Rs 836.25 crore in year ago period.
Other Income grew by 187.59 per cent at Rs 11.59 crore versus (Mar'21 Rs 4.03 crore). Operating Profit slipped by 9.25 per cent to Rs 291.30 crore as against Rs 320.99 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 19.50 per cent in March quarter. Interest grew by 176.64 per cent y-o-y to Rs 5.92 crore, while Taxation decreased by 100.68 per cent at Rs -0.34 crore (Mar'21 Rs 49.93 crore).
![](https://portfolio.investmentguruindia.com/uploads/news/insurance 123.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Axis Securities Ltd.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Wipro.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/2b1715f7e03b51b0ac9c014eb224fc1f.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/gdp22.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Geojit Financial Services.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Dollar retures 2.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/health22.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Arvind Kapil, MD and CEO, Poonawalla Fincorp.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/stock8.jpg)
Tag News
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/05/892c2d00d68c33104f9bb896e2cd4a96.jpg)
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales
![Alembic Pharmaceuticals surges on getting EIR for Solid Oral Formulation Facility at Vadodara](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/05/22be0ecb7dfcd46b119b708cd51da380.jpg)
![Alembic Pharmaceuticals gains on completing ANVISA GMP audit at API-III Facility without any observations](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/03/ac1cda4099cf0c445fd6d2081f02ab14.jpg)
![Alembic Pharmaceuticals trades higher on completing USFDA`s inspection at Derma Facility without any observations](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/03/6a3f74c50ac1ab127e5882adbac0bbb8.jpg)